1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Alopecia - Pipeline Review, H1 2016

Alopecia - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 148 pages

Alopecia - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Alopecia - Pipeline Review, H1 2016’, provides an overview of the Alopecia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alopecia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Alopecia
- The report reviews pipeline therapeutics for Alopecia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Alopecia therapeutics and enlists all their major and minor projects
- The report assesses Alopecia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Alopecia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Alopecia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alopecia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Alopecia - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Alopecia Overview 11
Therapeutics Development 12
Pipeline Products for Alopecia - Overview 12
Pipeline Products for Alopecia - Comparative Analysis 13
Alopecia - Therapeutics under Development by Companies 14
Alopecia - Therapeutics under Investigation by Universities/Institutes 16
Alopecia - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Alopecia - Products under Development by Companies 20
Alopecia - Products under Investigation by Universities/Institutes 23
Alopecia - Companies Involved in Therapeutics Development 24
Aclaris Therapeutics, Inc. 24
Allergan Plc 25
AndroScience Corporation 26
Berg LLC 27
BiologicsMD, Inc. 28
Bristol-Myers Squibb Company 29
Diffusion Pharmaceuticals LLC 30
Follicum AB 31
Histogen, Inc. 32
Hyundai Pharmaceutical Co., Ltd. 33
Incyte Corporation 34
Kuhnil Pharmaceutical Co., Ltd. 35
Lee's Pharmaceutical Holdings Limited 36
LEO Pharma A/S 37
NovaLead Pharma Pvt. Ltd. 38
Panacea Biotec Limited 39
Polichem S.A. 40
Quark Pharmaceuticals, Inc. 41
RepliCel Life Sciences, Inc. 42
RXi Pharmaceuticals Corporation 43
Sucampo Pharmaceuticals, Inc. 44
SWITCH Biotech LLC 45
Taisho Pharmaceutical Holdings Co., Ltd. 46
TetraLogic Pharmaceuticals 47
Tigo GmbH 48
Valeant Pharmaceuticals International, Inc. 49
Vida Therapeutics Inc. 50
Alopecia - Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Target 52
Assessment by Mechanism of Action 54
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 60
A-201 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
A-301 - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
abatacept - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
Antibodies to Inhibit Heparanase for Cancer - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
ASCJ-9 - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
bimatoprost - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
BMD-2341 - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
BRM-421 - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
calcitriol - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
CB-0301 - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
DHL-HisZnNa - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
diphencyprone - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
finasteride - Drug Profile 77
Product Description 77
Mechanism of Action 77
RandD Progress 77
finasteride - Drug Profile 78
Product Description 78
Mechanism of Action 78
RandD Progress 78
FOL-005 - Drug Profile 79
Product Description 79
Mechanism of Action 79
RandD Progress 79
FS-2 - Drug Profile 81
Product Description 81
Mechanism of Action 81
RandD Progress 81
Hair Stimulating Complex - Drug Profile 82
Product Description 82
Mechanism of Action 82
RandD Progress 82
HTB-005 - Drug Profile 84
Product Description 84
Mechanism of Action 84
RandD Progress 84
interferon beta-1b - Drug Profile 85
Product Description 85
Mechanism of Action 85
RandD Progress 85
KI-1104 - Drug Profile 86
Product Description 86
Mechanism of Action 86
RandD Progress 86
KI-1105 - Drug Profile 87
Product Description 87
Mechanism of Action 87
RandD Progress 87
LEO-124249 - Drug Profile 88
Product Description 88
Mechanism of Action 88
RandD Progress 88
minoxidil - Drug Profile 89
Product Description 89
Mechanism of Action 89
RandD Progress 89
NLP-602 - Drug Profile 90
Product Description 90
Mechanism of Action 90
RandD Progress 90
OLX-104 - Drug Profile 91
Product Description 91
Mechanism of Action 91
RandD Progress 91
PRD-006 - Drug Profile 92
Product Description 92
Mechanism of Action 92
RandD Progress 92
QPAL-1 - Drug Profile 93
Product Description 93
Mechanism of Action 93
RandD Progress 93
QPAL-2 - Drug Profile 94
Product Description 94
Mechanism of Action 94
RandD Progress 94
RCH-01 - Drug Profile 95
Product Description 95
Mechanism of Action 95
RandD Progress 95
Recombinant Proteins to Antagonize IFN-Gamma Receptor for Alopecia Areata and Graft Arteriosclerosis - Drug Profile 97
Product Description 97
Mechanism of Action 97
RandD Progress 97
RES-440 - Drug Profile 98
Product Description 98
Mechanism of Action 98
RandD Progress 98
RK-023 - Drug Profile 100
Product Description 100
Mechanism of Action 100
RandD Progress 100
ruxolitinib phosphate - Drug Profile 102
Product Description 102
Mechanism of Action 102
RandD Progress 102
setipiprant - Drug Profile 107
Product Description 107
Mechanism of Action 107
RandD Progress 107
SHP-141 - Drug Profile 108
Product Description 108
Mechanism of Action 108
RandD Progress 108
SM-04554 - Drug Profile 110
Product Description 110
Mechanism of Action 110
RandD Progress 110
Small Molecule for Androgenic Alopecia - Drug Profile 112
Product Description 112
Mechanism of Action 112
RandD Progress 112
Synthetic Peptide for Alopecia - Drug Profile 113
Product Description 113
Mechanism of Action 113
RandD Progress 113
TASP-0382088 - Drug Profile 114
Product Description 114
Mechanism of Action 114
RandD Progress 114
VTI-1000 Series - Drug Profile 115
Product Description 115
Mechanism of Action 115
RandD Progress 115
ZK-003 - Drug Profile 116
Product Description 116
Mechanism of Action 116
RandD Progress 116
Alopecia - Recent Pipeline Updates 117
Alopecia - Dormant Projects 138
Alopecia - Discontinued Products 141
Alopecia - Product Development Milestones 142
Featured News and Press Releases 142
Dec 04, 2015: Samumed Announces Increases in Both Hair Count and Hair Density Observed in Its Phase II Study for a Potential Treatment of Androgenetic Alopecia 142
Nov 23, 2015: Samumed Completes Phase II Study for Its Potential Treatment of Androgenetic Alopecia: Safety Data Show No Serious Adverse Events in Any Treated Patient 142
Nov 18, 2015: Samumed to Announce Clinical Data on Potential Treatment of Androgenetic Alopecia at the World Congress for Hair Research 143
Nov 02, 2015: TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata 143
Sep 22, 2015: KYTHERA Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss 144
Sep 04, 2014: FDA Approved Ruxolitinib Shown to Restore Hair Growth in Alopecia Patients 144
Oct 26, 2012: Glaucoma Drug Bimatoprost May Be Effective In Treating Alopecia, New Research In FASEB Journal Shows 145
Jul 23, 2012: Berg Pharma Launches Clinical Trial On BPM 31543 For Prevention Of Chemotherapy-induced Alopecia 145
Jan 24, 2011: R-Tech Ueno Completes Phase IIa Clinical Study Of RK-023 To Treat Androgenetic Alopecia 145
Oct 06, 2010: Cosmo Reports Positive Results In Alopecia Study With CB-03-01 146
Appendix 147
Methodology 147
Coverage 147
Secondary Research 147
Primary Research 147
Expert Panel Validation 147
Contact Us 147
Disclaimer 148

List of Tables
Number of Products under Development for Alopecia, H1 2016 12
Number of Products under Development for Alopecia - Comparative Analysis, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Number of Products under Development by Companies, H1 2016 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2016 16
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 18
Comparative Analysis by Early Stage Development, H1 2016 19
Products under Development by Companies, H1 2016 20
Products under Development by Companies, H1 2016 (Contd..1) 21
Products under Development by Companies, H1 2016 (Contd..2) 22
Products under Investigation by Universities/Institutes, H1 2016 23
Alopecia - Pipeline by Aclaris Therapeutics, Inc., H1 2016 24
Alopecia - Pipeline by Allergan Plc, H1 2016 25
Alopecia - Pipeline by AndroScience Corporation, H1 2016 26
Alopecia - Pipeline by Berg LLC, H1 2016 27
Alopecia - Pipeline by BiologicsMD, Inc., H1 2016 28
Alopecia - Pipeline by Bristol-Myers Squibb Company, H1 2016 29
Alopecia - Pipeline by Diffusion Pharmaceuticals LLC, H1 2016 30
Alopecia - Pipeline by Follicum AB, H1 2016 31
Alopecia - Pipeline by Histogen, Inc., H1 2016 32
Alopecia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016 33
Alopecia - Pipeline by Incyte Corporation, H1 2016 34
Alopecia - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H1 2016 35
Alopecia - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 36
Alopecia - Pipeline by LEO Pharma A/S, H1 2016 37
Alopecia - Pipeline by NovaLead Pharma Pvt. Ltd., H1 2016 38
Alopecia - Pipeline by Panacea Biotec Limited, H1 2016 39
Alopecia - Pipeline by Polichem S.A., H1 2016 40
Alopecia - Pipeline by Quark Pharmaceuticals, Inc., H1 2016 41
Alopecia - Pipeline by RepliCel Life Sciences, Inc., H1 2016 42
Alopecia - Pipeline by RXi Pharmaceuticals Corporation, H1 2016 43
Alopecia - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 44
Alopecia - Pipeline by SWITCH Biotech LLC, H1 2016 45
Alopecia - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H1 2016 46
Alopecia - Pipeline by TetraLogic Pharmaceuticals, H1 2016 47
Alopecia - Pipeline by Tigo GmbH, H1 2016 48
Alopecia - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 49
Alopecia - Pipeline by Vida Therapeutics Inc., H1 2016 50
Assessment by Monotherapy Products, H1 2016 51
Number of Products by Stage and Target, H1 2016 53
Number of Products by Stage and Mechanism of Action, H1 2016 55
Number of Products by Stage and Route of Administration, H1 2016 57
Number of Products by Stage and Molecule Type, H1 2016 59
Alopecia Therapeutics - Recent Pipeline Updates, H1 2016 117
Alopecia - Dormant Projects, H1 2016 138
Alopecia - Dormant Projects (Contd..1), H1 2016 139
Alopecia - Dormant Projects (Contd..2), H1 2016 140
Alopecia - Discontinued Products, H1 2016 141

List of Figures
Number of Products under Development for Alopecia, H1 2016 12
Number of Products under Development for Alopecia - Comparative Analysis, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 16
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 18
Comparative Analysis by Early Stage Products, H1 2016 19
Assessment by Monotherapy Products, H1 2016 51
Number of Products by Top 10 Targets, H1 2016 52
Number of Products by Stage and Top 10 Targets, H1 2016 52
Number of Products by Top 10 Mechanism of Actions, H1 2016 54
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 54
Number of Products by Routes of Administration, H1 2016 56
Number of Products by Stage and Routes of Administration, H1 2016 56
Number of Products by Molecule Types, H1 2016 58
Number of Products by Stage and Molecule Types, H1 2016 58

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Acyl CoA Desaturase ...

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Histamine H4 Recepto ...

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H2 2016

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.